ABC Efflux Transporters | BBB Assay | 고마바이오텍

PreadyPort-MDR1 

특징 

• MDR1 gene은 약물수송단백질인 P-glycoprotein (P-gp)을 encoding하는 유전자입니다. P-gp는 세포막에 존재하는 중요 당단백으로 약물배출에 관여하는 transporter 입니다. 
• MDR1 efflux transporter는 장내 흡수, 담즙 및 약물의 소변 배설, 중추 신경계로의 활성 분자 진입에 중요한 역할을 하는 유비쿼터스 조직 분포를 가지고 있습니다.
  
• PreadyPort-MDR1은 MDR1을 발현하는 분화된 MDCK II cell이 미리 seeding된 24well 혹은 96 transwell insert plate 입니다.
  
• PMDA, FDA, EMA에서는 BCRP, MDR1/P-gp를 reference efflux transporter로서 이용하도록 권고하고 있습니다. 

종류 

KRECE-CTR01 PreadyPort-CTRL (24 Transwell)

KRECE-CTR50 PreadyPort-CTRL (96 Transwell)

KRECE-MDR01 PreadyPort-MDR1 (24 Transwell)

KRECE-MDR02 PreadyPort-MDR1/CTRL 1:1 (24 Transwell)

KRECE-MDR50 PreadyPort-MDR1 (96 Transwell)

KRECE-MDR51 PreadyPort-MDR1/CTRL 1:1 (96 Transwell)

사용논문

• Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

• Aubets, J., Jansat, J-M., Salva, M., et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540. DOI: 10.1002/prp2.540.

• Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

• ICH M12 Drug Interaction Studies, 2022.

• FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

• EMA Guideline on Investigation of Drug Interactions, 2012. 

• PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

PreadyPort-BCRP

특징  

• BCRP (breast cancer resistance protein; ABCG2)는 대한 기질 특이성을 가진 high-capacity efflux transport로, 장벽 조직 및 배설 기관의 apical cell membrane에 존재합니다. 
• PreadyPort-BCRP는 BCRP를 발현하는 12일 분화된 MDCK II cell이 미리 seeding된 24well 혹은 96 transwell insert plate 입니다.
• PMDA, FDA, EMA에서는 BCRP, MDR1/P-gp를 reference efflux transporter로서 이용하도록 권고하고 있습니다. 
  
• 적용 :
  - BCRP substrates, inhibitors and inducers
  - BCRP transporter-based drug-drug interactions (concomitantly administered drugs)
  - Drug permeability by passive diffusion through a physiologically relevant barrier

종류 

KRECE-CTR01 PreadyPort-CTRL (24 Transwell)

KRECE-CTR50 PreadyPort-CTRL (96 Transwell)

KRECE-BCP01 PreadyPort-BCRP (24 Transwell)

KRECE-BCP02 PreadyPort-BCRP/CTRL 1:1 (24 Transwell)

KRECE-BCP50 PreadyPort-BCRP (96 Transwell)

KRECE-BCP51 PreadyPort-BCRP/CTRL 1:1 (96 Transwell)

사용논문 

• Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

• Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

• ICH M12 Drug Interaction Studies, 2022.

• FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

• EMA Guideline on Investigation of Drug Interactions, 2012.

• PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.